Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Proteomics International Laboratories Ltd. ( (AU:PIQ) ) just unveiled an announcement.
Proteomics International Laboratories Ltd has notified the market that 15,072 employee performance rights (ASX code: PIQAY) have lapsed as of 31 December 2025 because the conditions attached to those rights were not met or became incapable of being satisfied. The cessation modestly reduces the company’s potential future issued capital under its employee incentive arrangements but does not involve any new capital raising or change to existing listed securities, indicating a routine adjustment to its share-based remuneration structure.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.63 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd is an Australian-listed biotechnology company (ASX: PIQ) focused on developing and commercialising proteomics-based diagnostics and analytical services, particularly in the life sciences and medical research sectors.
Average Trading Volume: 367,678
Technical Sentiment Signal: Buy
Current Market Cap: A$107.3M
Find detailed analytics on PIQ stock on TipRanks’ Stock Analysis page.